Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer

NCT00322348 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00322348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
November 30, 2009
Enrollment
98 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer